Eli Lilly's Strong Q3 Raises the Bar, But Valuation Already Full

What happened

Eli Lilly reported exceptional third-quarter 2026 results, with revenue up 39% to $24.4 billion, driven by Mounjaro and Zepbound, and management raised full-year revenue guidance by $5.5 billion to a range of $91.0-$92.0 billion. However, the growth was heavily volume-driven, with a 53% increase in volume offset by a 15% decline in realized prices, underscoring rising payer pressure. The company highlighted diversification efforts through Foundayo, Retatrutide, and the Medicare Bridge program, but these remain early-stage: Foundayo contributed only $184 million in quarterly revenue, while Retatrutide is still in clinical trials. Inventories rose to $18.2 billion from $13.7 billion, and sales rebates and discounts climbed to $24.2 billion from $17.4 billion, suggesting the company is buying access. With the stock at $1,374.50 and trading at 45.9x earnings, the market has already priced in continued dominance and successful execution, leaving little margin for error.

Implication

Given the demanding valuation of 45.9x earnings and 42.2x EV/EBITDA, the risk-reward is balanced to unfavorable for new money at $1,374.50. A more attractive entry point would be near $1,220, where the margin of safety improves. The key monitorables for the next two quarters are whether tirzepatide volume continues to outrun price declines, and whether Foundayo revenue accelerates beyond its current $184 million quarterly base. If rebates and discounts continue to rise as a percentage of U.S. revenue beyond the current 2%, or if inventories grow faster than sales, it would signal deeper revenue-quality erosion. Conversely, evidence that Medicare/new-channel uptake is contributing materially and that retatrutide milestones stay on track could justify a higher valuation and warrant adding to positions.

Thesis delta

The investment thesis remains unchanged: Lilly owns the strongest obesity franchise, but the stock price already discounts sustained dominance and successful pipeline execution. The Q3 report and raised guidance confirm the strength but also raise the bar, as the market now expects even higher revenue and earnings, making the valuation even more demanding. Consequently, the existing WAIT rating is reinforced, with no change to conviction or price targets.